3 Result: Trevena
Pre-Market Movers: Marker Therapeutics Surges on MT-601 Potential, Trevena on Milestone Payment
May 31st, 2023
Marker Therapeutics, Inc. (Nasdaq: MRKR) shared positive pre-clinical data regarding their T cell product candidate, MT-601, which targets multiple tumor-associated antigens (multiTAA) in lymphoma cells, including those resistant to CD19 CAR T cell t. Read more
FREYR Battery and Trevena Surpass Estimates, SoFi Technologies Downgraded, PlayAGS Upgraded
May 15th, 2023
FREYR Battery (NYSE: FREY) has announced its first quarter 2023 financial results, reporting a loss of $0.09 per share. This result surpasses the consensus estimate of a loss of $0.29 per share. Despite the loss, the company's pre-market trading refl. Read more
Trevena and Immuron Make Strides in Medical Advancements with New Approvals and Collaborations, Imperial Petroleum Posts Record Revenues and Profitability, Resulting in a Surge in Stock Prices
May 08th, 2023
Trevena, Inc. (Nasdaq: TRVN) made a significant announcement that its partner in China, Jiangsu Nhwa, has received formal approval from the National Medical Products Administration for OLINVYK, a medication for adults who require intravenous opioid a. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login